SuperworthGRAIL price to sales ratio GRAL
Market value divided by revenue over the last twelve months, since 2025.
- Today, Oct 23, 2026
- 35.8×
- Peer median
- 6.4×
GRAIL's price to sales ratio is 35.8× as of Oct 23, 2026.
The median for 10 diagnostics and research stocks of a similar size is 6.4×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 35.8× | 12.0× | 38.7× |
| 2025 | 25.2× | 6.0× | 30.3× |
Against its peers
Companies in Medical - Diagnostics & Research nearest GRAIL's size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| GRALGRAIL | 35.8× |
| LNTHLantheus | 4.2× |
| BLLNBillionToOne | 12.8× |
| CAICaris Life Sciences | 9.1× |
| VCYTVeracyte | 6.9× |
| CDNACareDx | 7.8× |
| BIOBio-Rad Laboratories | 3.8× |
| RVTYRevvity | 6.1× |
| MEDPMedpace | 6.7× |
| LHLabcorp | 1.9× |
| DGXQuest Diagnostics | 2.3× |
| Peer median | 6.4× |
Where GRAIL ranks
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on GRAIL
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.